OPKO Health (NASDAQ:OPK) Stock, Quote.Headers.trade-ideas

OPKO Health

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.

Medical,Technology,Concept.

News

Movers

Opko Health shares are trading higher Thursday after the company announced a $100 million share repurchase program. Here&#39;s a look at what to know: 

Opko Health Stock Is Climbing: What&#39;s Going On?

CTAS, Cintas

Intraday Update

Markets

Trading Ideas

CHUY

COMM

CSIQ

CTAS

INFY

INTC

LEGN

MTLS

ROOT

VIRT

ZIMV

Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday

Rising,Medical,Cost,In,The,United,States

Health Care

After-Hours Center

Opko Health shares are trading higher after-hours Wednesday. The company announced it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx). 

Why Opko Health Shares Are Up After-Hours

OPKO Health Inc

Digital Holdings Inc

OPKO HEALTH ORD

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Outperform and maintains $2.25 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

During the last three months, 4 analysts shared their evaluations of OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for OPKO Health, revealing an average target of $2.81, a high estimate of $3.00, and a low estimate of $2.25. Highlighting a 9.94% decrease, the current average has fallen from the previous average price target of $3.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1726585238_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive OPKO Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$2.25</td>
<td>$1.50</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OPKO Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of OPKO Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for OPKO Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of OPKO Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OPK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OPKO Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into OPKO Health's Background</h2>
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
<h3>Key Indicators: OPKO Health's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: OPKO Health's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -31.36%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: OPKO Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -5.66%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): OPKO Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.78%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): OPKO Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.52%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: OPKO Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For OPKO Health

Piper Sandler analyst Edward Tenthoff reiterates OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Overweight and maintains $3 price target.

Reiteration

Piper Sandler Reiterates Overweight on OPKO Health, Maintains $3 Price Target

HC Wainwright &amp; Co. analyst Yi Chen reiterates OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Buy and maintains $3 price target.

HC Wainwright & Co. Reiterates Buy on OPKO Health, Maintains $3 Price Target

The acquisition includes&nbsp;BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health in the United States outside of New York and New Jersey, including certain patient service centers (PSCs), customer contracts and operating assets, which currently generate approximately $100 million in annual revenue.

General

Laboratory Corporation Of America Holdings

Labcorp Has Completed The Acquisition Of Select Assets Of And Opko Health's Bioreference Health For $237.5M

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Outperform and raises the price target from $1.5 to $2.25.

Barrington Research Maintains Outperform on OPKO Health, Raises Price Target to $2.25

WIIM

OPKO Health shares are trading higher after the company reported better-than-expected Q2 EPS results.

OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.09) by 88.89 percent. The company reported quarterly sales of $182.200 million which missed the analyst consensus estimate of $185.190 million by 1.61 percent. This is a 31.35 percent decrease over sales of $265.400 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

OPKO Health Q2 2024 GAAP EPS $(0.01) Beats $(0.09) Estimate, Sales $182.200M Miss $185.190M Estimate

Opko Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) shares are trading higher Thursday after the company announced a $100 million <a href="https://www.benzinga.com/pressreleases/24/07/g39835824/opko-health-announces-100-million-share-repurchase-program">share repurchase program.</a>
The Details:
Opko said it expects to fund the repurchase program from existing cash and cash equivalents, and future cash flows. The company had approximately 697 million shares outstanding as of June 30, 2024, and the new authorization represents approximately 10.1% of shares outstanding at the current stock price.
Read Next:<a href="https://www.benzinga.com/news/earnings/24/07/39826835/discover-reports-better-than-expected-q2-results-heres-the-details"> Discover Reports Better-Than-Expected Q2 Results: Here&#8217;s The Details</a>
&#8220;We believe OPKO&#8217;s shares are significantly undervalued and offer an attractive investment opportunity. Buying back shares supports our conviction in OPKO&#8217;s strategy as we continue to advance our pipeline in the clinic and streamline our diagnostic segment on a path to profitability,&#8221; said Phillip Frost, M.D., CEO of Opko Health.&nbsp;
Additionally, Opko announced a $250 million non-dilutive note <a href="https://www.benzinga.com/news/24/07/39827620/why-opko-health-shares-are-up-after-hours">purchase agreement </a>with HealthCare Royalty (HCRx) after the market close Wednesday. Opko said the purchase agreement is secured by its profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA, a once-weekly treatment to treat pediatric growth hormone deficiency.
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Opko Health shares are moving on heavy volume and are trading above the stock&#8217;s 50-day moving average of $1.31.&nbsp;
<h2 class="wp-block-heading">Should I Sell My OPK Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Opko Health have decreased by 27.39% in the past year. An investor who bought shares of Opko Health at the beginning of the year would take a loss of $0.03 per share if they sold it today. The stock has risen 24.15% over the past month, meaning an investor who bought shares on June 1 would see a capital gain of $0.12.
Opko Health shares have an all-time high of $5.15, representing 234.55% upside from current levels.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Opko Health stock currently has an RSI of 84.21, indicating overbought conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
OPK Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Opko Health shares are up 3.87% at $1.47 at the time of publication Thursday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39827454/what-happened-with-intel-stock-today">What Happened With Intel Stock Today?</a></li>
</ul>
Image: Shutterstock

Opko Health Stock Is Climbing: What's Going On?

U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday.
Shares of Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) rose during Thursday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39839582/cintas-beats-expectations-with-strong-q4-earnings-sets-ambitious-fy25-revenue-target">quarterly EPS and revenues</a>.
Cintas reported fourth-quarter earnings per share of $3.99, beating the street view of $3.80. The company registered quarterly revenues of $2.471 billion, beating the street view of $2.468 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Cintas shares gained 5.3% to $758.25 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) shares gained 47.6% to $37.29 after the company and Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) jointly announced that Darden will acquire Chuy's Holdings.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) jumped 19% to $2.0407. Amphenol announced plans to acquire mobile networks businesses from CommScope.</li>
<li>ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) shares rose 14.7% to $21.74.</li>
<li>Virtu Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) surged 13.2% to $26.61 after the company reported better-than-expected second-quarter financial results.</li>
<li>D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) shares gained 10.6% to $174.29 after the company reported better-than-expected third-quarter financial results and revised its FY24 guidance. Also, the company authorized a new $4 billion share repurchase.</li>
<li>OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) rose 8.5% to $1.54. The company announced a $100 million share repurchase program.</li>
<li>Canadian Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) surged 8.3% to $17.89.</li>
<li>Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) rose 7.5% to $59.12. HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterated Legend Biotech with a Buy and maintained a $73 price target.</li>
<li>Infosys Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) gained 7.4% to $22.07 as the company reported first-quarter revenue growth of 2.5% in constant currency terms year-on-year to $4.71 billion, beating the analyst consensus estimate of $4.65 billion.</li>
<li>Root, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) rose 7.4% to $85.29. Root is scheduled to host a conference call to discuss financial results for the second quarter on Wednesday, Aug. 7.</li>
<li>Materialise NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) jumped 7.2% to $5.85. Materialise is expected to release financial results for the second quarter on Wednesday, July 31.</li>
<li>BankUnited, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) gained 6.6% to $36.95 after the company reported better-than-expected quarterly financial results.</li>
<li>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) gained 6.5% to $260.95 after the company completed the acquisition of Cupertino Electric.</li>
<li>Meritage Homes Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) rose 6.1% to $201.54.</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) rose 6% to $135.83 in sympathy with D.R. Horton, which reported better-than-expected third-quarter financial results.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) gained 5.2% to $8.76 after the Financial Times reported that the company has discussed plans to split its digital streaming and studio businesses from its legacy television networks.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) gained 4.4% to $35.97.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39837094/jim-cramer-can-bless-general-dynamics-its-great-not-expensive">Jim Cramer &#8216;Can Bless&#8217; General Dynamics: &#8216;It&#8217;s Great, Not Expensive</a>&#8216;</li>
</ul>

Opko Health shares are trading higher. The company announced a $100 million share repurchase program.

Buybacks

OPKO Health Announces $100M Share Buyback Program

Piper Sandler analyst Edward Tenthoff maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Overweight and lowers the price target from $5 to $3.

Piper Sandler Maintains Overweight on OPKO Health, Lowers Price Target to $3

Opko Health Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) shares are trading higher after-hours Wednesday. The company announced it entered into a $250 million non-dilutive note purchase <a href="https://www.benzinga.com/pressreleases/24/07/g39825467/opko-health-and-healthcare-royalty-enter-into-250-million-note-purchase-agreement-secured-by-ngenl">agreement with HealthCare Royalty (HCRx). </a>
The Details: Opko said the purchase agreement is secured by its profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA, a once-weekly treatment to treat pediatric growth hormone deficiency. 
The $250 million note issued under the Note Purchase Agreement bears interest at the 3-month Secured Overnight Financing Rate (SOFR) subject to a 4% per annum floor, plus 7.5% per annum. The note has a final maturity date of July 2044 with the first four years requiring interest-only payments.
Read Next:<a href="https://www.benzinga.com/news/24/07/39796841/lucids-stock-drives-higher-on-2025-model-year-updates-whats-going-on"> Lucid&#8217;s Stock Drives Higher On 2025 Model Year Updates: What&#8217;s Going On?</a>
&#8220;This transaction with HCRx allows OPKO to retain a significant portion of NGENLA&#8217;s profit share payments in the near term and provides upside over the long term. It also permits OPKO to maintain the full benefit of the $100 million of remaining potential milestone payments from Pfizer,&#8221; said Phillip Frost, M.D., CEO of Opko.
&#8220;Additionally, it provides non-dilutive capital and financial flexibility to advance our research and development activities including our multispecific antibody programs, as well as potentially to repurchase shares of our common stock and convertible notes."
OPK Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Opko Health shares are up 7.07% after-hours at $1.52 at the time of publication Wednesday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39805320/what-happened-with-canopy-growth-stock-today">What Happened With Canopy Growth Stock Today?</a></li>
</ul>
Image: Shutterstock

OPKO Health Enters Into $250M Non-Dilutive Note Purchase Agreement With HealthCare Royalty Secured By Profit Share Payments From Pfizer For NGENLA

New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additional E-Commerce Platforms, in Brick-and-Mortar Retail Locations and Launch In-Country Digital Marketing Programs
COCONUT GROVE, Fla., July 2, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>, NXPLW)))) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced that it has expanded its e-commerce development program in China through a new agreement with a leading Chinese healthcare and nutritional products marketing and distribution services partner (the "Marketing Partner"). The Marketing Partner will provide NextPlat with a full range of creative content, brand marketing and product sales and distribution services and support the Company's&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4203578-1&amp;h=995620933&amp;u=https%3A%2F%2Fir.nextplat.com%2Fnews-events%2Fpress-releases%2Fdetail%2F108%2Fnextplats-florida-e-commerce-development-program-to-launch&amp;a=exclusive+joint+e-commerce+development+agreement+with+OPKO+Health+Europe+(%22OPKO%22)">exclusive joint e-commerce development agreement with OPKO Health Europe ("OPKO")</a>, a subsidiary of OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>).

NXPL

NextPlat Expands E-Commerce Program In China To Include Broad Retail Distribution And Adds Digital/Social Media Marketing Capabilities

The Dow Jones index closed lower by over 600 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Qurate Retail</h3>
<ul>
<li>The Trade: Qurate Retail, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRTEA#NASDAQ">QRTEA</a>) President/CEO David Rawlinson <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 100,000 shares</a> at an average price of $0.72. To acquire these shares, it cost around $71,878.</li>
<li>What's Happening: On May 8, Qurate Retail posted downbeat quarterly sales.</li>
<li>What Qurate Retail Does: Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries.</li>
</ul>
<h3 class="wp-block-heading">Ondas Holdings</h3>
<ul>
<li>The Trade: Ondas Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) Director Joseph V Popolo <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 100,000 shares at</a> an average price of $0.78. To acquire these shares, it cost around $78,232.</li>
<li>What's Happening: On May 15, Ondas Holdings posted in-line loss for its first quarter.</li>
<li>What Ondas Holdings Does: Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India.</li>
</ul>
<h3 class="wp-block-heading">OPKO Health</h3>
<ul>
<li>The Trade: OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) 10% owner Frost Gamma Investments Trust <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 100,000 shares</a> at an average price of $1.27. The insider spent around $126,937 to buy those shares. </li>
<li>What's Happening: On May 7, OPKO Health reported worse-than-expected first-quarter financial results.</li>
<li>What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs.</li>
</ul>
Read This Next: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38984458/top-5-tech-stocks-that-could-lead-to-your-biggest-gains-this-month">Top 5 Tech Stocks That Could Lead To Your Biggest Gains This Month</a>

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

ONDS

QRTEA

Ondas Holdings And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed above the $40,000 mark on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Tecogen</h3>
<ul>
<li>The Trade: Tecogen Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGEN#OTC">TGEN</a>) Director John Hatsopoulos <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 3,000 shares</a> at an average price of $0.75. To acquire these shares, it cost around $2,248.</li>
<li>What's Happening: On May 8, Tecogen reported revenues of $6.2 million and net loss of $1.1 million for the quarter ended March 31.</li>
<li>What Tecogen Does: Tecogen Inc, designs, manufactures, markets, and maintains high-efficiency, ultra-clean cogeneration products. It operates in three business segments, namely Products, Services, and Energy Production.</li>
</ul>
<h3 class="wp-block-heading">Standard BioTools</h3>
<ul>
<li>The Trade: Standard BioTools Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) Director Casdin Partners FO1-MSV, LP <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 1,352,072 shares at</a> an average price of $2.56. To acquire these shares, it cost around $3.46 million.</li>
<li>What's Happening: On May 8, Standard BioTools posted downbeat quarterly sales.</li>
<li>What Standard BioTools Does: Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster.</li>
</ul>
<h3 class="wp-block-heading">OPKO Health</h3>
<ul>
<li>The Trade: OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) 10% owner Frost Gamma Investments Trust &lt;a href=&#8221;https://www.benzinga.com/sec/insider-trades/&#8221;&gt;&lt;em&gt; acquired a total of 163,997 shares &lt;/em&gt;&lt;/a&gt; at an average price of $1.29. The insider spent around $211,195 to buy those shares.</li>
<li>What's Happening: On May 7, OPKO Health reported worse-than-expected first-quarter financial results.</li>
<li>What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko&#8217;s diagnostics business includes a core genetic testing operation.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/05/38911760/zoom-video-wix-com-and-3-stocks-to-watch-heading-into-monday">Zoom Video, Wix.com And 3 Stocks To Watch Heading Into Monday</a>

TGEN

$3.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

Shares of Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue <a href="https://www.benzinga.com/news/earnings/24/05/38682848/upstart-q1-earnings-revenue-beat-eps-beat-targeting-positive-ebitda-in-2024-and-more">guidance below estimates</a>.
Upstart reported first-quarter revenue of $128 million, which beat the consensus estimate of $124.867 million, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Upstart expects second-quarter revenue of approximately $125 million versus estimates of $140.83 million. The company anticipates a second-quarter adjusted EBITDA loss of approximately $25 million.
Upstart shares dipped 10.3% to $21.96 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Reborn Coffee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>) shares jumped 132.9% to $4.0297 after the company announced a significant expansion into the China market through a strategic Master License Agreement with IAID Co.</li>
<li>iSun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) gained 49% to $0.1966.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) jumped 36.4% to $1.48.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) rose 34% to $1.4099.</li>
<li>Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) shares gained 31.5% to $8.86 after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Cricut, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) gained 31% to $7.25 after the company reported better-than-expected first-quarter GAAP EPS results.</li>
<li>MaxCyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) rose 27.6% to $5.01 following upbeat quarterly results.</li>
<li>Ameresco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NASDAQ">AMRC</a>) gained 27.6% to $28.47 following strong quarterly results.</li>
<li>Davis Commodities Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>) rose 26.8% to $1.5580</li>
<li>Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) surged 26.5% to $17.11 following strong quarterly earnings.</li>
<li>American Public Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) rose 23.3% to $18.71 following upbeat quarterly results.</li>
<li>Globus Medical, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) gained 23.3% to $63.35 after the company reported better-than-expected first-quarter financial results and raised its FY24 guidance.</li>
<li>Kyndryl Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) jumped 21.6% to $25.25 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>PowerSchool Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWSC#NYSE">PWSC</a>) gained 21.2% to $20.17 following a report suggesting Bain is pursuing a takeover of the company.</li>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) rose 21.1% to $24.02 following better-than-expected first-quarter earnings.</li>
<li>Arko Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKO#NYSE">ARKO</a>) gained 20.3% to $5.15 following first-quarter earnings.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) gained 19% to $3.5609 following strong first-quarter earnings.</li>
<li>Hyster-Yale Materials Handling, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) surged 18.2% to $69.74 following UPBEAT first-quarter earnings.</li>
<li>Alpha and Omega Semiconductor Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) jumped 17.7% to $26.22 after reporting strong quarterly results.</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) gained 17.2% to $1.1529 after declining over 6% on Tuesday.</li>
<li>Oddity Tech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) gained 15.8% to $36.19 after the company reported better-than-expected first-quarter financial results and issued FY24 EPS guidance above estimates.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) climbed 15.5% to $32.82 after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance.</li>
<li>Louisiana-Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) gained 15% to $83.93 following better-than-expected first-quarter financial results.</li>
<li>RingCentral, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) rose 14.8% to $34.42 after the company reported better-than-expected first-quarter financial results and raised its FY24 guidance.</li>
<li>Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) rose 14.5% to $1.89 as the company posted a narrower-than-expected quarterly loss.</li>
<li>Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) gained 14.2% to $27.09 after the company reported better-than-expected quarterly sales results.</li>
<li>Hannon Armstrong Sustainable Infrastructure Capital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NASDAQ">HASI</a>) gained 13.9% to $29.84 following upbeat earnings.</li>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) rose 13% to $15.75 after the company reported mixed first quarter financial results.</li>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) gained 11.7% to $3.6650 after the company posted better-than-expected results for its first quarter.</li>
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) gained 10.1% to $90.01 after the company reported first quarter financial results.</li>
<li>Cirrus Logic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) jumped 9.6% to $99.93 as the company posted better-than-expected results for its fourth quarter.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares gained 9.5% to $0.81 after the company reported better than expected first-quarter financial results.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) gained 8.8% to $18.08 following better-than-expected first-quarter results.</li>
<li>Veeco Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) rose 6.9% to $40.08 following upbeat results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Treace Medical Concepts, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) shares dipped 60.8% to $4.3650 after the company reported first-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>DoubleVerify Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) fell 38.5% to $18.79 after the company reported first-quarter financial results.</li>
<li>Inspire Medical Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) fell 34.3% to $161.35 following first-quarter results.</li>
<li>Definitive Healthcare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) dipped 32.2% to $4.9150 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) fell 31.1% to $0.7653 following quarterly results.</li>
<li>Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) fell 28.4% to $18.24 after Liberty Tripadvisor and the Special Committee ceased discussions with third parties with respect to a potential transaction.</li>
<li>ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) shares fell 25.2% to $11.98 after the company reported first-quarter financial results and issued second-quarter guidance below estimates.</li>
<li>LegalZoom.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) dipped 23.3% to $9.35 after the company reported worse-than-expected first-quarter financial results and issued second-quarter revenue guidance below estimates.</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) fell 22.7% to $21.78 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Grocery Outlet Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) dipped 22.2% to $20.17 after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Flywire Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) shares declined 21.7% to $16.08 after the company reported worse-than-expected first-quarter EPS results and issued second-quarter revenue guidance below estimates.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) dipped 20.6% to $8.31 following first-quarter results.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) fell 19.8% to $61.76 following first-quarter earnings..</li>
<li>Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) dipped 18.6% to $37.26 following first-quarter earnings..</li>
<li>Acutus Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) fell 17.1% to $0.1020 after jumping 15% on Tuesday. Nasdaq, last week, notified the company that it has not regained compliance with listing rule 5550(a)(2).</li>
<li>Shoals Technologies Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) shares fell 14.1% to $7.56 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Masimo Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) fell 13.8% to $117.23 following first-quarter earnings. The company&#8217;s second-quarter guidance midpoint was below consensus estimates.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) dipped 13.6% to $14.99 following worse-than-expected first-quarter financial results.</li>
<li>STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) dipped 11.8% to $41.10 following quarterly results.</li>
<li>Volcon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) shares declined 11.8% to $0.26 after the company reported a year-over-year decrease in first-quarter sales results.</li>
<li>Qualys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) fell 10.1% to $149.21 after the company reported first-quarter earnings and issued second-quarter revenue guidance below estimates.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) fell 9.1% to $31.74 following third-quarter earnings.</li>
<li>Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) dipped 8.6% to $64.40. Uber posted weaker-than-expected fiscal first-quarter financial results.</li>
<li>Coupang, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) fell 7.8% to $21.78 after the company reported mixed first-quarter financial results.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) shares declined 6.3% to $71.37 following first-quarter results.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) shares declined 6.2% to $41.56 following first-quarter results.</li>
<li>A-Mark Precious Metals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) shares fell 5.5% to $38.14 following fiscal third quarter 2024 results.</li>
<li>Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) shares fell 5.5% to $59.86 following first-quarter results.</li>
<li>OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) shares fell 5.4% to $1.23 after the company reported worse-than-expected first-quarter financial results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38702433/airbnb-gears-up-for-q1-print-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Airbnb Gears Up For Q1 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

AFIB

AFRM

ALAB

AMRC

AMRK

AOSL

APEI

ARKO

BROS

CLOV

CPNG

CRCT

CRUS

DTCK

ELAN

FLYW

GMED

Hannon Armstrong Sustainable Infrastructure Capital

HASI

INOD

INSP

ISUN

LAZR

LYFT

MASI

MCRB

MXCT

MYGN

NIVF

PWSC

QLYS

REBN

RPTX

SATS

SHLS

SHOP

SIGA

SMLR

STAA

SWIM

TEVA

TIVC

TMCI

TOST

TRIP

TWLO

UBER

UPST

VECO

VLCN

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Pfizer: Tracking Well Above The Industry

OPKO Health Q2 Earnings Preview

OPKO Health GAAP EPS of -$0.01 beats by $0.09, revenue of $182.2M misses by $2.49M

OPKO Health, Inc. (OPK) Q2 2024 Earnings Call Transcript

Roth MKM says Small-Cap Value reaches key technical support, lists 14 "bullish" stocks

Not Enough To Keep OPKO Health Flying

Opko Health ( ($OPK) ) has shared an update. BioReference Health, an OPKO Health subsidiary, has successfully settled its debts by repaying roughly...

Opko Health Subsidiary Restructures with Strategic Sale and Debt Settlement

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Opko Health (OPK – Research Report). The associated price target remains the...

Opko Health's Strategic Moves and Pipeline Progress Prompt Buy Rating

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Opko Health (OPK – Research Report) today and set a price target of $3.00. The com...

Opko Health (OPK) Receives a Buy from Piper Sandler

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Opko Health (OPK – Research Report), with a price target of ...

Opko Health's Strategic Moves and Financial Prospects Bolster Buy Rating

ABBV

AVUV

BMYMP

DFAS

DFSV

FYBR

KNSA

KVYO

LGND

NVSEF

PLXS

SCHA

SGMO

SLYV

SPSM

TEVJF

WGSWW

Press Releases

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

OPKO Health to Participate in the Jefferies Global Healthcare Conference

Small Cap

NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner

Financing

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

OPKO Health Announces $100 Million Share Repurchase Program

OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

ENTX

RXMD

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

OPKO Health

OPKO Health (OPK) Forecast

OPKO Health (NASDAQ:OPK) Stock, Quote.Headers.trade-ideas